secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-07-13T11:05:37+00:00
Accession:  0001493152-26-032925
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix adds Medicare Part D coverage for TONMYA, expanding access to 145M lives by Jan 2027
--------------------------------------------------------------------------------

- New Medicare agreement effective Jan 1, 2027 adds ~9M Medicare Part D lives (16% of U.S. Medicare).
- Combined with prior commercial GPO deals and Medicaid, TONMYA coverage reaches ~145M lives (46% of U.S. covered lives).
- Sales force to expand by 50 reps by mid-Q3 2026, total ~150 reps.
- TONMYA is a first-in-class, non-opioid sublingual cyclobenzaprine for fibromyalgia.
- Positive launch metrics cited: new prescribers, new patients, total and refill prescriptions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226032925/0001493152-26-032925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226032925/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer